Walvax BioTech (300142) - Total Liabilities
Based on the latest financial reports, Walvax BioTech (300142) has total liabilities worth CN¥3.31 Billion CNY (≈ $485.06 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Walvax BioTech to track the company's year-over-year net asset growth rate.
Walvax BioTech - Total Liabilities Trend (2007–2025)
This chart illustrates how Walvax BioTech's total liabilities have evolved over time, based on quarterly financial data. See 300142 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Walvax BioTech Competitors by Total Liabilities
The table below lists competitors of Walvax BioTech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nuscale Power Corp
NYSE:SMR
|
USA | $38.43 Million |
|
Brederode
LSE:0QWB
|
UK | €680.00K |
|
Par Pacific Holdings Inc
NYSE:PARR
|
USA | $2.66 Billion |
|
Hypera S.A
SA:HYPE3
|
Brazil | R$15.38 Billion |
|
Ebro Foods
MC:EBRO
|
Spain | €1.60 Billion |
|
BKV Corporation
NYSE:BKV
|
USA | $1.06 Billion |
|
Centuri Holdings, Inc.
NYSE:CTRI
|
USA | $1.45 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Walvax BioTech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Walvax BioTech market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Walvax BioTech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Walvax BioTech (2007–2025)
The table below shows the annual total liabilities of Walvax BioTech from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.26 Billion ≈ $330.33 Million |
-29.82% |
| 2024-12-31 | CN¥3.22 Billion ≈ $470.67 Million |
-23.30% |
| 2023-12-31 | CN¥4.19 Billion ≈ $613.64 Million |
-3.51% |
| 2022-12-31 | CN¥4.35 Billion ≈ $635.99 Million |
+18.25% |
| 2021-12-31 | CN¥3.68 Billion ≈ $537.81 Million |
+104.18% |
| 2020-12-31 | CN¥1.80 Billion ≈ $263.40 Million |
+33.16% |
| 2019-12-31 | CN¥1.35 Billion ≈ $197.81 Million |
-31.83% |
| 2018-12-31 | CN¥1.98 Billion ≈ $290.15 Million |
-14.48% |
| 2017-12-31 | CN¥2.32 Billion ≈ $339.27 Million |
-17.21% |
| 2016-12-31 | CN¥2.80 Billion ≈ $409.78 Million |
-13.41% |
| 2015-12-31 | CN¥3.23 Billion ≈ $473.25 Million |
+17.36% |
| 2014-12-31 | CN¥2.76 Billion ≈ $403.25 Million |
-13.81% |
| 2013-12-31 | CN¥3.20 Billion ≈ $467.88 Million |
+149.66% |
| 2012-12-31 | CN¥1.28 Billion ≈ $187.41 Million |
+336.18% |
| 2011-12-31 | CN¥293.62 Million ≈ $42.97 Million |
-32.58% |
| 2010-12-31 | CN¥435.52 Million ≈ $63.73 Million |
+105.98% |
| 2009-12-31 | CN¥211.43 Million ≈ $30.94 Million |
+3.88% |
| 2008-12-31 | CN¥203.54 Million ≈ $29.78 Million |
+1.84% |
| 2007-12-31 | CN¥199.86 Million ≈ $29.25 Million |
-- |
About Walvax BioTech
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, grou… Read more